Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GSK2618960 for primary Sjögren's syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• GSK2618960 (GSK2618960)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Autoimmune Diseases | Phase 2 | Status: WITHDRAWN